Olon
A Stalwart in Generic API and CDMO Services

As evidenced by the jarring events of last year, changes in drug market demands can create immense growth opportunities for API manufacturers and CDMOs alike. While the pharmaceutical sector has developed substantially, organizations still face hurdles in choosing a CDMO partner or a Generic API provider that not only adheres to the innumerable drug regulation policies but also has the expertise and know-how to deliver exceptional drug products that can broaden revenue streams. At this juncture of choosing a suitable partner, companies ought to turn their sights to Olon S.p.A—a global leader in the development and production of APIs and an adept provider of CDMO services. Olon quickly grew into a powerhouse in the Italian chemical-pharmaceutical market by the end of 2003 after its acquisition of many Italian chemical processing plants. Striding forward in global expansion and economic growth under the watchful gaze of Paolo Tubertini, over the last five years the pharma giant acquired Infa Group, the US Chemical Bioscience Research Division, Capua Bioservices and established Olon API India.

Equipped with an arsenal of manufacturing plants across the globe and with several decades of experience in supporting pharmaceutical, biotech, food, chemical and bio-industrial companies, Olon has established its undeniable worth as a reliable outsourcing partner for CDMO services. “Our dual strategy of helping the client remedy the issues they’re facing and also provide a result that effectively achieves their mission is what sets us apart from the crowd,” says Paolo Tubertini, Managing Director at Olon. Collaborating with universities and powered by a workforce of more than 200 highly-skilled researchers, the organization functions on a result-centric ideology of helping clients achieve their objectives, irrespective of the complexity.

Olon provides an integrated package of chemical synthesis and biological processing services, which clients can use to manage their drug manufacturing projects while staying compliant with regulations. “We sell over 300 compounds on the merchant market worldwide.

We sell over 300 compounds worldwide. So, from a regulatory standpoint, Olon is much more competent in the regulations of different countries than other competitors

So, from a regulatory standpoint, Olon is much more competent in the regulations of different countries than other competitors,” adds Tubertini. Another competitive edge that Olon possesses is the eight manufacturing facilities built in Italy. Strategically founded in an environment with accessible university services, machinery producers, analytical labs, technicians, and more, Olon’s facilities promise an expediency seldom seen in the industry.

Among a multitude of successful client engagements, a case study that highlights Olon’s commitment to solving the client’s issues was when the team helped a customer implement an API that no other organization in the drug manufacturing space could effectively deliver. The API compound was risky to synthesize, but Olon set out to find a solution that could mitigate the risk and analyze the root cause of the safety issue. Within four months, Olon not only helped the client revamp their processes from a chemical standpoint but the team also improved the client’s machinery to match the specifications that they needed. “By identifying and remedying an issue that no one else could, we have now become the leading producer of that specific API,” explains Tubertini.

More recently, during the pandemic period, Olon strategy has been to promote cooperation along all the supply chain in order to manage the demand for products and, finally, avoid any disruption of supplying. Olon, as reliable Partner, has globally maintained continuous production.

Company strategy for CDMO business focuses on expansion in new markets. As Tubertini concludes, “Olon CDMO has a well-established presence in the pharma market of large molecules by microbial biomanufacturing. Now we are actively and significantly investing in food and specialty ingredients in general. Offering our expertise in CDMO services and biotechnologies as well, we are able to support innovative food biotech companies to accelerate the development of new products, combining it with more sustainable manufacturing approach.”